Developer docs
API playgroundTry for free, no card

Search company profiles

NanOlogy

Full company profile

uuid000ax13

Namestring
NanOlogy
Legal namestring
NanOlogy, LLC
Websiteurl
nanology.us
Company typeenum
Private
Founded yearint
2015
Descriptiontext

NanOlogy, LLC is a privately held, clinical-stage interventional oncology drug developer founded in 2015 as a joint venture among DFB Pharmaceuticals (Fort Worth, TX), CritiTech (Lawrence, KS), and US Biotest (San Luis Obispo, CA). The company is headquartered in Fort Worth, Texas, operates with 1–10 employees, and has no disclosed funding rounds, external investors, or commercial product revenue. Its purpose is to advance a local, intratumoral precision-therapy approach for solid tumors that minimizes systemic toxicity relative to conventional IV chemotherapy.

The company's core technology is the PURCISION particle-engineering platform, which uses supercritical fluid carbon dioxide to reduce taxane API crystals by up to 400-fold into stable submicron or micron particles of pure drug, forming Large Surface Area Microparticles (LSAMs) optimized for intratumoral delivery. These particles function as a depot at the disease site, releasing drug locally at high concentration while maintaining negligible systemic plasma levels. The intellectual property estate comprises over 130 issued patents globally, including composition-of-matter claims (US 9,814,685; US 10,507,195; US 10,993,927; US 11,123,322) valid through June 2036 and parallel filings in major jurisdictions. The product portfolio comprises NanoPac (submicron paclitaxel sterile suspension for intratumoral, intracystic, and inhaled delivery), NanoDoce (submicron docetaxel for intravesical use in bladder cancer), SOR007 (topical submicron paclitaxel for cutaneous metastases), and LSAM-Cisplatin for pediatric DIPG. Clinical activity spans seven completed trials and 170+ treated patients across six solid tumor types (pancreas, lung, bladder, peritoneal, ovarian, prostate, dermal) with no confirmed drug-related serious adverse events.

NanOlogy's business model is pre-commercial: revenue is generated only upon FDA approval and product launch, with no current pricing or distribution channel established. Development proceeds under the FDA 505(b)2 regulatory pathway, and GTM activity is centered on conference presentations (ASCO, BIO, ISPNO, AACR, SITC), peer-reviewed publications, and enterprise partnering outreach to pharmaceutical companies. The company appointed David J. Arthur as CEO in December 2025 and John M. Goldberg, MD as CMO in January 2026, alongside unveiling a DIPG program and planning an IND submission for mid-2026.

Short descriptiontext

NanOlogy is a privately held, clinical-stage oncology company developing intratumoral submicron particle drug formulations (NanoPac, NanoDoce, LSAM-Cisplatin) using its PURCISION technology platform to treat solid tumors, including a new pediatric DIPG program, with minimal systemic toxicity.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFort Worth, United States
HQ citystring
Fort Worth
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intratumoral drug delivery, oncology drug development, submicron particle therapeutics, interventional oncology drugs, cancer microparticle platform
Industry2 codes
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Intratumoral Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

As a pre-revenue clinical-stage oncology company, NanOlogy does not currently generate revenue. The company is advancing its LSAM investigational drug portfolio (NanoPac, NanoDoce, LSAM-Cisplatin) through clinical trials toward regulatory approval and commercial distribution. Revenue would be generated through product sales upon FDA approval.

nanology.us
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1NanoPac
Description

Sterile suspension of submicron particle paclitaxel for intratumoral, intracystic, or inhaled delivery in treatment of solid tumors including pancreatic cancer, lung cancer, and pancreatic mucinous cysts.

nanology.us
+2 more records
Core offering1 text field

NanOlogy develops and clinically advances investigational oncology drugs in the form of Large Surface Area Microparticles (LSAMs) of proven chemotherapeutics, produced via its proprietary PURCISION™ particle engineering platform. Its drug portfolio comprises NanoPac® (submicron particle paclitaxel suspension), NanoDoce® (submicron particle docetaxel suspension), SOR007 (submicron particle paclitaxel topical ointment), and LSAM-Cisplatin, all designed for direct intratumoral, intracystic, intravesical, inhaled, or topical delivery to treat solid tumors with high local drug concentration and minimal systemic toxicity.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 170+ patients treated with no confirmed drug-related serious adverse events
+5 more records
Product overview1 text field

NanOlogy is advancing a local precision approach for solid tumor treatment using its proprietary PURCISION™ particle engineering technology that forms Large Surface Area Microparticles (LSAMs) of cancer drugs designed for intratumoral delivery. The product portfolio includes NanoPac® (submicron particle paclitaxel sterile suspension) for multiple solid tumors, NanoDoce® (submicron particle docetaxel sterile suspension) for bladder and genitourinary cancers, SOR007 topical ointment for cutaneous metastases, and LSAM-Cisplatin for pediatric brain tumors. These investigational drugs are optimized for local delivery to maximize drug concentration at tumor sites while minimizing systemic toxicity.

Product and service4 records
1NanoPac®
CategoryInvestigational oncology drug
Description

Sterile suspension of submicron particle paclitaxel designed for intratumoral, intracystic, and inhalation delivery to treat solid tumors including pancreatic cancer, lung cancer, ovarian cancer, prostate cancer, and pancreatic mucinous cysts.

2NanoDoce®
CategoryInvestigational oncology drug
Description

Sterile suspension of submicron particle docetaxel for intratumoral and intravesical delivery in bladder cancer and other genitourinary cancers.

3SOR007 Topical Ointment
CategoryInvestigational oncology drug
Description

Submicron particle paclitaxel suspended in a topical anhydrous base for treatment of cutaneous metastases of breast cancer and actinic keratosis.

4LSAM-Cisplatin
CategoryInvestigational oncology drug
Description

Large Surface Area Microparticle formulation of cisplatin for stereotactic intratumoral administration targeting diffuse intrinsic pontine glioma (DIPG), a rare and fatal pediatric brainstem tumor.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or Integration
Description

CritiTech, Inc. of Lawrence, KS is a co-founder of NanOlogy and the licensor of the submicron particle production technology (PURCISION). The patented production process reduces taxane API crystals into stable submicron particles. CritiTech licensed the technology to DFB Soria for dermatology fields outside oncology.

2US Biotest, Inc.
Strategic tierCoreTypeTechnology or Integration
Description

US Biotest, Inc. of San Luis Obispo, CA is a co-founder of NanOlogy. The company was formed along with DFB Pharmaceuticals and CritiTech to finance and clinically develop the submicron particle technology platform for local, sustained delivery of therapeutic agents.

nanology.us
Strategic tierCoreTypeStrategic or Co-development Partner
Description

DFB Soria is a DFB-owned affiliate that developed the topical anhydrous ointment formulation of submicron particle paclitaxel (SOR007). DFB Soria licensed the topical formulation to NanOlogy for oncology use and independently conducted Phase 2 trials in actinic keratosis. NanOlogy and DFB Soria share investigational drug programs in dermatology applications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

NanOlogy conducts clinical trials in partnership with leading medical institutions including Cedars-Sinai Medical Center (Simon Lo, MD), Baylor College of Medicine (Mohamed Othman, MD), Parkview Cancer Institute (Neil Sharma, MD), University of Florida Health (Hiren Mehta, MD), and other major cancer centers across the United States.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Commercial-stage cell therapy company whose lead products (Amtagvi, Lifileucel) are autologous tumor-infiltrating lymphocyte therapies administered intratumorally or regionally. Comparable to NanOlogy in advancing intratumoral oncology modalities toward commercialization, though operating at much larger scale.

TypeBroad incumbent
Description

Global oncology incumbent whose Keytruda franchise dominates the immune checkpoint inhibitor market and would be the natural combination partner for LSAM-ICI programs. Relevant comparable for understanding how NanOlogy's combination-therapy optionality could be monetized through a major-pharma deal.

TypeEmerging player
Description

Clinical-stage company developing intratumoral RNAi-based immunotherapies (INTASYL platform) designed to be administered directly into tumors. Comparable to NanOlogy as an emerging intratumoral modality developer with similar local-delivery strategic positioning.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing intratumoral oncolytic peptides (LTX-315 and LTX-401) that induce tumor cell death and immune activation at the injection site. Comparable to NanOlogy as an emerging player using intratumoral administration to drive local and systemic anti-tumor immune response.

5Istari Oncology
TypeEmerging player
Description

Clinical-stage immuno-oncology company developing PVSRIPO, an intratumoral oncolytic virus therapy initially targeting recurrent glioblastoma. Comparable to NanOlogy in pursuing intratumoral administration of a locally active agent with systemic immune effects.

TypeDirect peer
Description

Clinical-stage oncology company developing intratumoral chemotherapy formulations (INT230-6) that combine cisplatin, vinorelbine and celecoxib for direct intratumoral injection. Most directly comparable to NanOlogy in combining reformulated cytotoxic drugs with direct local delivery to bypass systemic toxicity.

7OncoSec Medical
TypeDirect peer
Description

Clinical-stage immuno-oncology company focused on intratumoral gene electroporation delivery (TAVO), enabling local expression of IL-12 to drive immune response. Comparable to NanOlogy as a developer of intratumoral oncology therapies targeting local immune and tumor effects.

8Celsion Corporation
TypeDirect peer
Description

Clinical-stage oncology company developing ThermoDox, a heat-activated liposomal doxorubicin formulation administered intratumorally with localized hyperthermia. Shares NanOlogy's strategy of reformulating a known cytotoxic for direct local delivery to improve the therapeutic index.

9Bristol Myers Squibb
TypeBroad incumbent
Description

Major oncology incumbent with checkpoint inhibitor franchises (Opdivo, Yervoy) that represent the dominant combination partner referenced in NanOlogy's LSAM-ICI patent strategy. Relevant as the most likely large-pharma acquirer or partner for NanOlogy's combination programs.

TypeBroad incumbent
Description

Clinical and commercial-stage nanomedicine company whose lead asset Hensify (NbTx1) is a hafnium oxide nanoparticle injected intratumorally to enhance radiotherapy. Closely comparable to NanOlogy in using proprietary nanoparticle engineering to localize therapeutic effect within the tumor microenvironment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NanOlogy

Intratumoral Oncology Therapeuticsnanology.us

NanOlogy is a privately held, clinical-stage oncology company developing intratumoral submicron particle drug formulations (NanoPac, NanoDoce, LSAM-Cisplatin) using its PURCISION technology platform to treat solid tumors, including a new pediatric DIPG program, with minimal systemic toxicity.

What NanOlogy does

NanOlogy, LLC is a privately held, clinical-stage interventional oncology drug developer founded in 2015 as a joint venture among DFB Pharmaceuticals (Fort Worth, TX), CritiTech (Lawrence, KS), and US Biotest (San Luis Obispo, CA). The company is headquartered in Fort Worth, Texas, operates with 1–10 employees, and has no disclosed funding rounds, external investors, or commercial product revenue. Its purpose is to advance a local, intratumoral precision-therapy approach for solid tumors that minimizes systemic toxicity relative to conventional IV chemotherapy.

The company's core technology is the PURCISION particle-engineering platform, which uses supercritical fluid carbon dioxide to reduce taxane API crystals by up to 400-fold into stable submicron or micron particles of pure drug, forming Large Surface Area Microparticles (LSAMs) optimized for intratumoral delivery. These particles function as a depot at the disease site, releasing drug locally at high concentration while maintaining negligible systemic plasma levels. The intellectual property estate comprises over 130 issued patents globally, including composition-of-matter claims (US 9,814,685; US 10,507,195; US 10,993,927; US 11,123,322) valid through June 2036 and parallel filings in major jurisdictions. The product portfolio comprises NanoPac (submicron paclitaxel sterile suspension for intratumoral, intracystic, and inhaled delivery), NanoDoce (submicron docetaxel for intravesical use in bladder cancer), SOR007 (topical submicron paclitaxel for cutaneous metastases), and LSAM-Cisplatin for pediatric DIPG. Clinical activity spans seven completed trials and 170+ treated patients across six solid tumor types (pancreas, lung, bladder, peritoneal, ovarian, prostate, dermal) with no confirmed drug-related serious adverse events.

NanOlogy's business model is pre-commercial: revenue is generated only upon FDA approval and product launch, with no current pricing or distribution channel established. Development proceeds under the FDA 505(b)2 regulatory pathway, and GTM activity is centered on conference presentations (ASCO, BIO, ISPNO, AACR, SITC), peer-reviewed publications, and enterprise partnering outreach to pharmaceutical companies. The company appointed David J. Arthur as CEO in December 2025 and John M. Goldberg, MD as CMO in January 2026, alongside unveiling a DIPG program and planning an IND submission for mid-2026.

NanOlogy firmographics

Firmographics
Name
NanOlogy
Legal name
NanOlogy, LLC
Website
https://nanology.us
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
NanOlogy is a privately held, clinical-stage oncology company developing intratumoral submicron particle drug formulations (NanoPac, NanoDoce, LSAM-Cisplatin) using its PURCISION technology platform to treat solid tumors, including a new pediatric DIPG program, with minimal systemic toxicity.
Ownership category
akta.pro rank

NanOlogy industry classification

Industry
Product category
Intratumoral Oncology Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Intratumoral drug delivery
  • Oncology drug development
  • Submicron particle therapeutics
  • Interventional oncology drugs
  • Cancer microparticle platform

Where NanOlogy is headquartered

Location

Headquarters

HQ city
Fort Worth
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NanOlogy business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Drug Development and Commercialization: As a pre-revenue clinical-stage oncology company, NanOlogy does not currently generate revenue. The company is advancing its LSAM investigational drug portfolio (NanoPac, NanoDoce, LSAM-Cisplatin) through clinical trials toward regulatory approval and commercial distribution. Revenue would be generated through product sales upon FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

NanOlogy product offering

Product offering

Core offering

NanOlogy develops and clinically advances investigational oncology drugs in the form of Large Surface Area Microparticles (LSAMs) of proven chemotherapeutics, produced via its proprietary PURCISION™ particle engineering platform. Its drug portfolio comprises NanoPac® (submicron particle paclitaxel suspension), NanoDoce® (submicron particle docetaxel suspension), SOR007 (submicron particle paclitaxel topical ointment), and LSAM-Cisplatin, all designed for direct intratumoral, intracystic, intravesical, inhaled, or topical delivery to treat solid tumors with high local drug concentration and minimal systemic toxicity.

Product overview

NanOlogy is advancing a local precision approach for solid tumor treatment using its proprietary PURCISION™ particle engineering technology that forms Large Surface Area Microparticles (LSAMs) of cancer drugs designed for intratumoral delivery. The product portfolio includes NanoPac® (submicron particle paclitaxel sterile suspension) for multiple solid tumors, NanoDoce® (submicron particle docetaxel sterile suspension) for bladder and genitourinary cancers, SOR007 topical ointment for cutaneous metastases, and LSAM-Cisplatin for pediatric brain tumors. These investigational drugs are optimized for local delivery to maximize drug concentration at tumor sites while minimizing systemic toxicity.

Differentiator

Problem solved

Functional benefit

Brands

  • NanoPac: Sterile suspension of submicron particle paclitaxel for intratumoral, intracystic, or inhaled delivery in treatment of solid tumors including pancreatic cancer, lung cancer, and pancreatic mucinous cysts.
  • NanoDoce
  • SOR007

Products and services

  • NanoPac® Sterile suspension of submicron particle paclitaxel designed for intratumoral, intracystic, and inhalation delivery to treat solid tumors including pancreatic cancer, lung cancer, ovarian cancer, prostate cancer, and pancreatic mucinous cysts.
  • NanoDoce® Sterile suspension of submicron particle docetaxel for intratumoral and intravesical delivery in bladder cancer and other genitourinary cancers.
  • SOR007 Topical Ointment Submicron particle paclitaxel suspended in a topical anhydrous base for treatment of cutaneous metastases of breast cancer and actinic keratosis.
  • LSAM-Cisplatin Large Surface Area Microparticle formulation of cisplatin for stereotactic intratumoral administration targeting diffuse intrinsic pontine glioma (DIPG), a rare and fatal pediatric brainstem tumor.

Quantifiable outcome

  • 170+ patients treated with no confirmed drug-related serious adverse events
  • +5 more outcomes

Companies that use NanOlogy

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles3 records

NanOlogy technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

NanOlogy partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • CritiTech, Inc.coreTechnology or IntegrationCritiTech, Inc. of Lawrence, KS is a co-founder of NanOlogy and the licensor of the submicron particle production technology (PURCISION). The patented production process reduces taxane API crystals into stable submicron particles. CritiTech licensed the technology to DFB Soria for dermatology fields outside oncology.
  • US Biotest, Inc.coreTechnology or IntegrationUS Biotest, Inc. of San Luis Obispo, CA is a co-founder of NanOlogy. The company was formed along with DFB Pharmaceuticals and CritiTech to finance and clinically develop the submicron particle technology platform for local, sustained delivery of therapeutic agents.
  • DFB Soria, LLCcoreStrategic or Co-development PartnerDFB Soria is a DFB-owned affiliate that developed the topical anhydrous ointment formulation of submicron particle paclitaxel (SOR007). DFB Soria licensed the topical formulation to NanOlogy for oncology use and independently conducted Phase 2 trials in actinic keratosis. NanOlogy and DFB Soria share investigational drug programs in dermatology applications.
  • Clinical Trial Sites and Medical InstitutionscoreStrategic or Co-development PartnerNanOlogy conducts clinical trials in partnership with leading medical institutions including Cedars-Sinai Medical Center (Simon Lo, MD), Baylor College of Medicine (Mohamed Othman, MD), Parkview Cancer Institute (Neil Sharma, MD), University of Florida Health (Hiren Mehta, MD), and other major cancer centers across the United States.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

NanOlogy competitors and assessment

Company assessment

Broad incumbents

  • Iovance Biotherapeutics: Commercial-stage cell therapy company whose lead products (Amtagvi, Lifileucel) are autologous tumor-infiltrating lymphocyte therapies administered intratumorally or regionally. Comparable to NanOlogy in advancing intratumoral oncology modalities toward commercialization, though operating at much larger scale.
  • Merck & Co. Global oncology incumbent whose Keytruda franchise dominates the immune checkpoint inhibitor market and would be the natural combination partner for LSAM-ICI programs. Relevant comparable for understanding how NanOlogy's combination-therapy optionality could be monetized through a major-pharma deal.
  • Bristol Myers Squibb: Major oncology incumbent with checkpoint inhibitor franchises (Opdivo, Yervoy) that represent the dominant combination partner referenced in NanOlogy's LSAM-ICI patent strategy. Relevant as the most likely large-pharma acquirer or partner for NanOlogy's combination programs.
  • Nanobiotix: Clinical and commercial-stage nanomedicine company whose lead asset Hensify (NbTx1) is a hafnium oxide nanoparticle injected intratumorally to enhance radiotherapy. Closely comparable to NanOlogy in using proprietary nanoparticle engineering to localize therapeutic effect within the tumor microenvironment.

Emerging players

  • Phio Pharmaceuticals: Clinical-stage company developing intratumoral RNAi-based immunotherapies (INTASYL platform) designed to be administered directly into tumors. Comparable to NanOlogy as an emerging intratumoral modality developer with similar local-delivery strategic positioning.
  • Lytix Biopharma: Clinical-stage immuno-oncology company developing intratumoral oncolytic peptides (LTX-315 and LTX-401) that induce tumor cell death and immune activation at the injection site. Comparable to NanOlogy as an emerging player using intratumoral administration to drive local and systemic anti-tumor immune response.
  • Istari Oncology: Clinical-stage immuno-oncology company developing PVSRIPO, an intratumoral oncolytic virus therapy initially targeting recurrent glioblastoma. Comparable to NanOlogy in pursuing intratumoral administration of a locally active agent with systemic immune effects.

Direct peers

  • Intensity Therapeutics: Clinical-stage oncology company developing intratumoral chemotherapy formulations (INT230-6) that combine cisplatin, vinorelbine and celecoxib for direct intratumoral injection. Most directly comparable to NanOlogy in combining reformulated cytotoxic drugs with direct local delivery to bypass systemic toxicity.
  • OncoSec Medical: Clinical-stage immuno-oncology company focused on intratumoral gene electroporation delivery (TAVO), enabling local expression of IL-12 to drive immune response. Comparable to NanOlogy as a developer of intratumoral oncology therapies targeting local immune and tumor effects.
  • Celsion Corporation: Clinical-stage oncology company developing ThermoDox, a heat-activated liposomal doxorubicin formulation administered intratumorally with localized hyperthermia. Shares NanOlogy's strategy of reformulating a known cytotoxic for direct local delivery to improve the therapeutic index.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

NanOlogy social profiles

Digital presence

NanOlogy financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NanOlogy leadership team

Management profile

Number of profiles

Profiles5 records

NanOlogy subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

NanOlogy funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NanOlogy M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NanOlogy

What does NanOlogy do?

NanOlogy develops and clinically advances investigational oncology drugs in the form of Large Surface Area Microparticles (LSAMs) of proven chemotherapeutics, produced via its proprietary PURCISION™ particle engineering platform. Its drug portfolio comprises NanoPac® (submicron particle paclitaxel suspension), NanoDoce® (submicron particle docetaxel suspension), SOR007 (submicron particle paclitaxel topical ointment), and LSAM-Cisplatin, all designed for direct intratumoral, intracystic, intravesical, inhaled, or topical delivery to treat solid tumors with high local drug concentration and minimal systemic toxicity.

Is NanOlogy a public or private company?

NanOlogy is a private company. It is classified as corporate owned and is currently operating.

When was NanOlogy founded?

NanOlogy was founded in 2015. It employs 11 to 50 people.

Where is NanOlogy based?

NanOlogy is headquartered in Fort Worth, United States, in the North America region.

How does NanOlogy make money?

One revenue line is on record: drug Development and Commercialization.

Who are NanOlogy's main competitors?

Broad incumbents on record are Iovance Biotherapeutics, Merck & Co., Bristol Myers Squibb and Nanobiotix. Emerging players are Phio Pharmaceuticals, Lytix Biopharma and Istari Oncology. Direct peers are Intensity Therapeutics, OncoSec Medical and Celsion Corporation.

Does NanOlogy have an API?

No public API is recorded for NanOlogy.

What industry is NanOlogy in?

NanOlogy's product category is Intratumoral Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireNanOlogy, LLC CEO David J. Arthur Discusses Their PURCISION™ Technology Advancing Intratumoral Therapy to Treat CancerNanOlogy, LLC CEO David J. Arthur discussed the company's PURCISION™ technology platform, which uses supercritical fluid carbon dioxide to form microparticles of cancer drugs optimized for intratumoral delivery directly to tumors, minimizing systemic toxicity. The company has conducted seven clinical trials across six solid tumor types and is developing LSAM-Cisplatin for diffuse intrinsic pontine glioma (DIPG), a rare and fatal pediatric brainstem tumor. Intratumoral therapy is gaining momentum with nearly 200 clinical trials underway, and large pharmaceutical companies like J&J are increasingly investing in the space.Pulse 2.0NanOlogy Names John Goldberg Fractional Chief Medical Officer to Advance LSAM Oncology PipelineNanOlogy appointed John M. Goldberg, MD, as fractional chief medical officer to advance its intratumoral therapy pipeline. The company plans to initiate a clinical trial for its diffuse intrinsic pontine glioma program in late 2026 and move adult solid tumor drugs into later-stage studies.PR NewswireNanOlogy Appoints John M. Goldberg, MD as Chief Medical Officer to Further its Preclinical & Clinical Large Surface Area Microparticle Investigational Drug PortfolioNanOlogy, LLC, a clinical-stage oncology company based in Fort Worth, Texas, appointed John M. Goldberg, MD as fractional Chief Medical Officer to advance its Large Surface Area Microparticle (LSAM) drug portfolio. Goldberg brings over 20 years of drug development experience, including roles at Rafael Holding, Oncorus, H3 Biomedicine (a subsidiary of Eisai), and Agenus. The company plans to initiate a clinical trial for its Diffuse Intrinsic Pontine Glioma (DIPG) program targeting pediatric brain cancer in late 2026.Dallas InnovatesNanOlogy Names CEO as Its Tumor-Targeted Cancer Drugs Near Key Regulatory MilestonesNanOlogy, a Fort Worth-based clinical-stage oncology company, has appointed veteran biopharma executive David Arthur as its new CEO as it advances toward later-stage development and commercialization of its LSAM drug portfolio. Arthur, who previously led Salarius Pharmaceuticals and spent over two decades at Eli Lilly and Boehringer Ingelheim, brings more than 35 years of pharmaceutical experience to guide the company through its next phase. The company is completing IND-enabling studies for a rare pediatric brainstem tumor program targeting DIPG and plans to submit an Investigational New Drug application to the FDA in mid-2026.PR NewswireNanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug PortfolioNanOlogy, LLC, a private clinical-stage oncology company, appointed David Arthur as Chief Executive Officer; Arthur previously served as CEO of Salarius Pharmaceuticals where he took the company public on NASDAQ and brings over 35 years of pharmaceutical experience. The company has completed clinical trials in 6 solid tumors with its Large Surface Area Microparticle (LSAM) investigational drugs and plans to submit an Investigational New Drug application to the FDA in mid-2026 for a rare pediatric brainstem tumor treatment. The appointment is intended to accelerate NanOlogy's drug development activities, business development plans, and efforts to identify strategic and financial partners.PR NewswireNanOlogy Unveils Drug Development Program for Rare Pediatric Brainstem TumorNanOlogy, LLC announced the development of a new drug program targeting diffuse intrinsic pontine glioma (DIPG), a lethal pediatric brain tumor. The company is progressing towards clinical trials planned for late 2026 with an IND application for LSAM-Cisplatin, aiming to improve targeted delivery and reduce systemic toxicity.Dallas InnovatesFort Worth Biotech NanOlogy Gets U.S. Patent for New Cancer TreatmentNanOlogy received a U.S. patent for treating cancer by combining intratumoral large surface area microparticle taxanes with systemic immune checkpoint inhibitors. The patent is valid until 2038, and the company has treated over 170 patients with no confirmed serious adverse events. It also completed enrollment of 18 patients in a Phase 2a lung cancer trial, with final data expected in Q3 2023.BioSpaceNanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic CystsNanOlogy published results from a clinical trial of intracystic LSAM-PTX in mucinous pancreatic cysts, with 19 subjects completing the study. Cyst volume reduced by 10-78% in 71% of subjects, and no dose-limiting toxicities occurred. The company plans further research to evaluate whether the treatment can decrease progression rates.